Unlicensed Cannabis Products in New York Contaminated with Harmful Substances

Dec.02.2022
Unlicensed Cannabis Products in New York Contaminated with Harmful Substances
An industry report found illegal marijuana sales in New York contain harmful bacteria, heavy metals, and toxic pesticides.

A report released on Wednesday reveals that some marijuana products sold in unlicensed stores in New York are not only illegal but contaminated with harmful bacteria, heavy metals, and toxic pesticides.


The association conducted laboratory tests on smokable cannabis, edible candies, and vaporizers purchased from 20 tobacco shops and pharmacies. They found eight different contaminants, including E. coli, salmonella, nickel, and lead, which are prohibited. According to a report from the New York Medical Marijuana Industry Association, a state trade organization, the investigation also revealed that some products had incorrect labeling of their strength.


The association represents licensed healthcare pharmacy operators in New York. It stated that the investigation's results highlight the concerns of elected officials and regulatory agencies regarding the danger posed by the reckless growth of retail stores in the state, which falsely claim that their products are legal.


At present, legal sales of marijuana in New York are limited to patients of 38 medical dispensaries operated by the association. However, prior to the release of this report, regulatory authorities granted licenses to 36 retail dispensaries in the state's first batch of approvals. The regulatory authorities stated that legal sales of recreational marijuana will begin in December.


The industry association stated in its report that "just as the imperial government was preparing to achieve this important goal, new illegal operators have emerged, seizing the tail of the highly respected legacy market, endangering public health and safety as well as the long-term success of legitimate operators.


For years, medical pharmacy operators have been frustrated by their exclusion from the New York retail market due to the prevalence of unlawful storefronts operating without regulation or repercussions. The report aims to pressure authorities to restrict illegal sales, as the healthcare industry seeks modifications to proposed regulations that would require them to pay at least $3 million to enter the retail market.


According to laboratory results, these tests were authorized by Curaleaf, a national chain with four locations in New York, currently facing fines, lawsuits, and product recalls in at least five states as well as license revocations in Oregon.


In Kura Sushi's statement, it defended the reputation of the company by pointing out that the suspension in Oregon is the first time in the 12 years of operation of the chain. A senior female spokesperson stated that this incident involves mislabeled products, and the discovery proves that supervision of the industry is working and regulatory agencies are also taking note of the company's cooperation.


She said that illegal markets in New York or any other state do not have this type of regulatory mechanism.


A newspaper has obtained a report from a basic laboratory test, but no independent verification of any testing results has been completed. Experts advise caution when interpreting these findings, noting that bacteria die when exposed to smoke and some metals and pesticides are considered safe in low amounts. Officials from the city government and cannabis regulatory agencies have stated that they are reviewing the report.


Overall, tests revealed that 16 out of 40 products were found to contain pollutants. Nine products contained tetrahydrocannabinol (THC), the intoxicating compound found in marijuana, at levels lower than what was advertised on their labels. However, analysis showed that one type of gummy candy claimed to have 100 milligrams of THC per piece on its label, but actually contained twice that amount.


The most common pollutants found in cannabis products are Escherichia coli and Salmonella, which were detected in nine different items, particularly loose bud and pre-rolled joints. National regulations prohibit the sale of cannabis products contaminated with these bacteria to consumers. Both types of bacteria can cause infections, often resulting in symptoms such as diarrhea, vomiting, fever, and cramps. In severe cases, they can be life-threatening.


The CEO of Talon Analytical, a laboratory licensed by the state, Michael Bianco, has stated that the tested products do not meet the standards set in New York. The company has tested illegal products for their clients, which are mostly medical marijuana companies.


The spokesperson for the Cannabis Control Office, Aaron Ghitelman, stated that the report confirms officials' long-standing claims about the risks of unregulated products and the necessity of shutting down unlicensed storefronts. The agency's governing board passed regulation last week denying licenses to individuals who sell marijuana in unlicensed storefronts or vehicles, or in any other way falsely claiming to be operating legally.


The office is currently involved in a cross-departmental joint law enforcement pilot with the city. Mayor Eric Adams has stated that this initiative has resulted in the confiscation of over 100,000 items and the issuance of 300 civil and criminal violations.


Officials did not indicate whether they will take action against any specific companies that were involved in the sale of tested products mentioned in the report.


2FIRSTS will continue to provide updates on this issue, with further information available on the '2FIRSTS APP'. Scan the QR code below to download the app.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

UK Vape Duty Starts in October as Hayati, DOJO and Others Launch Lower-Capacity Products With Lower Per-Unit Tax
UK Vape Duty Starts in October as Hayati, DOJO and Others Launch Lower-Capacity Products With Lower Per-Unit Tax
The UK's Vaping Products Duty will take effect on October 1, 2026, at a flat rate of £2.20 per 10ml of vaping liquid. Ahead of implementation, DOJO, PIXL and Hayati have introduced or been reported to be adding lower-capacity tiers alongside larger products. DOJO has added a 6ml BLAST7K Fresh below its 10ml BLAST10K Fresh, PIXL offers both a 12ml 8000 and a 6ml 5K, while retailer Ninja Vapes says Hayati is preparing a 7ml 4K alongside its existing 12ml 6K. The pattern points to a growing lower-capacity tier in the UK market, although the brands have not all explicitly linked the changes to the new duty.
Sep.23
German Bundestag Passes Tobacco Tax Hikes: Vape Liquid Duty to Reach €0.44/ml, Heated Tobacco Taxes to Rise and Cigarettes Seen Near €12 a Pack
German Bundestag Passes Tobacco Tax Hikes: Vape Liquid Duty to Reach €0.44/ml, Heated Tobacco Taxes to Rise and Cigarettes Seen Near €12 a Pack
Germany's Bundestag passed amendments to the Tobacco Tax Act on October 15, 2026, setting out annual excise tax increases from 2027 through 2030 for e-cigarette liquids, heated tobacco, cigarettes and other tobacco products. Under the Finance Committee's amended bill, duty on qualifying e-liquids will rise from €0.32/ml in 2026 to €0.44/ml in 2030, an increase of 37.5%. Heated tobacco will retain its tax calculation based on 80% of the corresponding cigarette excise duty. The average price of a 20-cigarette pack is projected to approach €12 by 2030, with some brands potentially reaching €14. The legislation is projected to generate approximately €11.8 billion in additional tax revenue over four years and remains subject to further legislative procedures.
Regulations
Oct.19
Imperial Brands Sees Double-Digit NGP Growth as Sixth Year of Tobacco Revenue Gains Backs £1.5 Billion Buyback
Imperial Brands Sees Double-Digit NGP Growth as Sixth Year of Tobacco Revenue Gains Backs £1.5 Billion Buyback
Imperial Brands reaffirmed its FY26 guidance in its October 8 pre-close trading update, forecasting double-digit net revenue growth in next-generation products and share gains across heated tobacco, vape and modern oral. Tobacco net revenue is expected to grow at a low-single-digit rate, marking a sixth consecutive year of growth. The company has completed its £1.45 billion FY26 share repurchase and announced a £1.5 billion buyback for FY27. Group adjusted operating profit is expected to increase 3% to 5%, while free cash flow is forecast to exceed £2.2 billion.
Oct.09
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
A commentary published in the international open-access, peer-reviewed Harm Reduction Journal argues that randomized controlled trials remain central to evaluating smoking cessation efficacy but cannot alone capture real-world uptake, complete switching, longer-term use and population impact of non-combustible nicotine products such as e-cigarettes, heated tobacco and nicotine pouches. The authors frame impact as “reach × efficacy” and call for real-world evidence to complement RCTs. Three days after publication, the FDA authorized three JUUL2 products and highlighted complete switching among adult smokers in explaining its decision, providing a timely regulatory backdrop to the debate.
Sep.08
U.S. Military Could Test Nicotine Pouches and Vapes for Smoking Cessation as Washington Examiner Cites ZYN and Potential $4 Billion Reduction in Related Defense Costs
U.S. Military Could Test Nicotine Pouches and Vapes for Smoking Cessation as Washington Examiner Cites ZYN and Potential $4 Billion Reduction in Related Defense Costs
The House-passed FY2027 National Defense Authorization Act includes a provision authorizing the defense secretary to conduct a one-year smoking-cessation pilot for active-duty service members. Section 707 lists counseling, nicotine gum and patches alongside what the bill calls "electric nicotine delivery systems," nicotine pouches and heat-not-burn products. A recent Washington Examiner op-ed cited ZYN as an example in arguing for the provision, but the legislation does not name any commercial brand or supplier. ZYN is made by PMI-owned Swedish Match USA, with specified products holding FDA marketing authorizations and modified risk orders.
Sep.20
Product | Philip Morris Korea Launches TEREA Limona Pearl, Expanding Fresh Blend Capsule Lineup to Five
Product | Philip Morris Korea Launches TEREA Limona Pearl, Expanding Fresh Blend Capsule Lineup to Five
Philip Morris Korea launched TEREA Limona Pearl in South Korea on August 31, 2026, expanding the TEREA Fresh Blend capsule tobacco stick lineup from four variants to five. Designed for the IQOS ILUMA series, the new stick combines a capsule with what the company calls a Fresh Filter. Philip Morris Korea describes the product as offering an aromatic, refreshing flavor profile with a cooling sensation, with an additional fresh note released when the capsule is crushed. The recommended retail price is KRW 4,800 per pack, with sales through IQOS stores and convenience stores nationwide. No reliable evidence has been found that the same Limona Pearl SKU was previously officially launched in another major IQOS market.
Sep.01